Catalyst Biosciences Inc Stock
Catalyst Biosciences Inc Stock
With 7 Buy predictions and not the single Sell prediction the community is currently very high on Catalyst Biosciences Inc.
With a target price of 22 € there is potential for a 4134.84% increase which would mean more than doubling the current price of 0.52 € for Catalyst Biosciences Inc.
Our community identified positive and negative aspects for Catalyst Biosciences Inc stock for the coming years. 1 users see the criterium "Worthwhile Investment for the next years" as a plus for the Catalyst Biosciences Inc stock. On the other hand our users think that "Worthwhile Investment for the next years" could be a problem in the future.
Pros and Cons of Catalyst Biosciences Inc in the next few years
Pros
?
G***** c******* t* c**********
?
S********** s********
?
B****
Cons
?
C******** o* t** e**********
?
W********* I********* f** t** n*** y****
?
M***** P*******
Tell us your opinion to access the 'Wisdom of the Crowds'
Performance of Catalyst Biosciences Inc vs. its peers
| Security | Change(%) | 1w | 1m | 1y | YTD | 3y | 5y |
|---|---|---|---|---|---|---|---|
| Catalyst Biosciences Inc | - | - | - | - | - | - | - |
| Rockwell Medical Inc. | 0.680% | -5.195% | -17.700% | -28.711% | 7.908% | -63.057% | -91.198% |
| Pacira Pharmaceuticals | 0.970% | -0.962% | 1.980% | -7.207% | -4.630% | -48.756% | -60.762% |
| Savara Inc. | 3.070% | -15.207% | -8.341% | 49.029% | -21.830% | 158.938% | 154.172% |
Comments
Crescent Biopharma (CBIO) had its price target lowered by HC Wainwright from $25.00 to $22.00. They now have a "buy" rating on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) is now covered by analysts at Guggenheim. They set a "buy" rating and a $35.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat
Crescent Biopharma (NASDAQ:CBIO) had its "buy" rating reaffirmed by analysts at HC Wainwright. They now have a $25.00 price target on the stock.
Show more
Ratings data for CBIO provided by MarketBeat